Starpharma Holdings Ltd.'s nanoscale drug delivery technology shows enhanced safety and durable responses in phase II trials compared to standard of care therapies in patients with advanced colorectal and ovarian cancer. Read More
Hasten Biopharmaceutical Co. Ltd. has licensed greater China rights to Lib Therapeutics Inc.’s next-generation PCSK9 inhibitor lerodalcibep in a deal worth up to $325 million. Read More
Hanmi Science Co. Ltd. is rolling out a new obesity pipeline with five candidates under its relatively new leadership with Lim Ju-hyun, the eldest daughter of Hanmi Pharmaceutical Co. Ltd. founder Lim Sung-ki, who serves as president of Hanmi’s global strategy division. Songpa-gu, Seoul-based Hanmi Science is the holding group of its main drug development and production arm, Hanmi Pharmaceutical, and its wholesaler arm, Online Pharm. Read More
The Samsung Life Science Fund made its fourth equity investment into a South Korean antibody-drug conjugate (ADC) developer, Aimedbio Inc., to round out its investment portfolio padded with three other firms, including Jaguar Gene Therapy LLC, Senda Biosciences Inc. and Araris Biotech AG. Read More
Innovent Biologics Inc. announced a HKD$2.37 billion (US$306 million) placement on the Hong Kong Stock Exchange (HKEX) to advance its late-stage pipeline, including mazdutide, a GLP-1R/GCGR dual agonist for diabetes and obesity. The company plans to offer 68 million new shares priced at HKD$34.92, which represents an 8.8% discount to the previous closing price of HKD$38.30 per share, the company said in a filing on the HKEX. Morgan Stanley is the sole placing agent. Read More
Insilico Medicine Inc. struck an out-licensing deal with Exelixis Inc. for its small-molecule USP1-inhibitor candidate called ISM-3091, the company said on Sept. 12, standing to gain $80 million in up-front payments. Read More
Five years after Gilead Sciences Inc. gave up on momelotinib in the wake of two phase III failures in myelofibrosis, the JAK1/2 and ACVR1 inhibitor has found its way to the market in the hands of GSK plc. Branded Ojjaara, the drug gained U.S. FDA approval for use in intermediate- or high-risk myelofibrosis patients with anemia regardless of prior administration with JAK inhibitors such as Jakafi (ruxolitinib, Incyte Corp.). Read More
Biopharma deal values through August are down 13.05% year-over-year, while the number of deals has fallen by 18.51% compared to 2022. M&A value, meanwhile, is down just 3.6% from last year. Through August, 2023 saw 885 biopharma deals worth $111.87 billion, compared to 1,086 deals totaling $128.66 billion in the same period in 2022. The first eight months of 2021 saw 1,386 deals worth $121.22 billion, 1,381 deals valued at $129.96 billion in 2020 and 1,051 deals worth $111.93 billion in 2019. Read More
New and updated clinical data presented by biopharma firms at the International Association for the Study of Lung Cancer, 2023 World Conference on Lung Cancer, including: Astrazeneca, Daiichi. Read More
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Asieris, Caliway, Foresee, Hutchmed, Innocare, J Ints, Sinovac,Takeda, Urovant. Read More
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: 2seventy, Aclipse, Beigene, Bionomics, Chong Kun Dang, Hasten, Lib, JW, Merck & Co., Nona, Pharmazz, PT Kalbe Farma, PT Kalbe Genexine, Salipro, Shanghai Henlius, Sumitomo, Sun. Read More
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Adel, Astellas, Aston, Astrazeneca, Bioray, Biosyngen, Daiichi Sankyo, Dizal, Innocare, Oscotec, Takeda. Read More
